Brief: Actinium Pharmaceuticals Inc Reports 2 Remissions And 67% ORR In Patients With A Tp53 Mutation In The Phase 1 Portion Of The Actimab-A Venetoclax Combination Trial In Patients With Relapsed Or Refractory Aml At The 63Rd Ash Annual Meeting
14/12/2021 13:47
Dec 14 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM PHARMACEUTICALS, INC. REPORTS 2 REMISSIONS AND
67% ORR
IN PATIENTS WITH A TP53 MUTATION IN THE PHASE 1 PORTION OF THE
ACTIMAB-A VENETOCLAX COMBINATION TRIAL IN PATIENTS WITH RELAPSED
OR REFRACTORY AML AT THE 63RD ASH ANNUAL MEETING
* ACTINIUM PHARMACEUTICALS INC - ACTINIUM TO EXPLORE
DEVELOPMENT
STRATEGY FOR PATIENTS WITH TP53 MUTATION
Source text for Eikon: ID:nPn76j8jWa
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities